advertisement
Biotech company Pfizer on Wednesday, 18 November, said that a final analysis of clinical-trial data from its COVID-19 vaccine trial shows that the shot is 95 percent effective and that vaccine also protects older people from the infection, Bloomberg reported. T
“The Phase 3 study of our COVID-19 vaccine candidate has met all primary efficacy endpoints. The study reached 170 confirmed cases of COVID19, with the vaccine candidate BNT162b2 demonstrating 95 percent efficacy beginning 28 days after the first dose,” a statement from the company read, according to ANI.
The Pfizer-BioNTech data said that the vaccine’s efficacy in people older than 65 was more than 94 percent, according to Bloomberg.
Wednesday’s announcement paves the way for Pfizer to apply for the first US regulatory authorisation for a coronavirus vaccine within days. In a statement, the companies announced that the safety milestone required by the US FDA for Emergency Use Authorisation (EUA) has been achieved and that they plan to submit a request within days to the FDA.
An earlier preliminary analysis, results of which were announced on 9 November, had shown that the COVID-19 vaccine being developed by Pfizer Inc. and BioNTech SE prevented more than 90 percent of infections. Those findings were based on a preliminary analysis and Phase 3 trials of the vaccine were still underway at the time.
(With inputs from Bloomberg and ANI.)
(At The Quint, we question everything. Play an active role in shaping our journalism by becoming a member today.)